|
시장보고서
상품코드
2050480
엘리퀴스 시장 : 적응증별, 강도별, 연령층별, 제형별, 유통 채널별, 지역별Eliquis Market, By Indication, By Strength, By Age Group, By Dosage Form, By Distribution Channel, By Geography |
||||||
엘리퀴스 시장 규모는 2026년에 83억 3,000만 달러로 추정되고 있으며, 2033년까지 120억 3,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.4%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 83억 3,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 5.40% | 예측 금액(2033년) | 1,230억 달러 |
전 세계 항응고제 시장은 제약 산업에서 매우 중요한 부분을 차지하고 있으며, 세계에서 가장 널리 처방되는 항응고제 중 하나에 초점을 맞추고 있습니다. 브리스톨마이어스스퀴브와 화이자가 개발한 엘리퀴스(성분명: 아픽사반)는 제 Xa인자 억제제로 분류되는 직접경구용 항응고제(DOAC)입니다. 이 획기적인 약물은 심방세동, 심부정맥혈전증, 폐색전증 등 다양한 혈전색전증 치료의 판도를 바꾸어 놓았습니다. 이 시장은 다양한 치료 용도 및 지역에 걸친 엘릭큐어의 제조, 유통 및 상업화를 포괄합니다. 전 세계 의료 시스템이 환자 예후 개선을 최우선 과제로 삼고 와파린과 같은 기존 항응고제를 대체할 수 있는 대안을 모색하는 가운데, 엘리퀴스는 우수한 효능 프로파일, 출혈 위험 감소, 정기적인 모니터링의 필요성 제거로 인해 선호되는 대안으로 부상하고 있습니다. 이 시장의 발전은 의료진의 채택률 증가, 적응증 확대, 첨단 항응고 요법에 대한 환자들의 인식 증가로 특징지을 수 있습니다.
시장 역학
세계의 엘러큐스 시장은 주로 몇 가지 강력한 요인에 의해 주도되고 있으며, 이러한 요인들이 결합되어 국제 의료 시장 전체의 확장을 촉진하고 있습니다. 전 세계에서 심방세동, 정맥혈전색전증 및 기타 심혈관 질환의 유병률 증가가 기본적인 성장 요인으로 작용하고 있으며, 특히 고령화 및 생활습관 관련 위험 요인으로 인해 이러한 추세는 더욱 강화되고 있습니다. 의료진이 와파린과 같은 기존 항응고제보다 엘리퀴스를 선호하는 이유는 우수한 안전성 프로파일, 예측 가능한 약동학, 정기적인 모니터링이 필요 없어 환자의 복약 순응도와 삶의 질을 크게 향상시킬 수 있기 때문입니다. 개선합니다. 광범위한 임상시험 데이터를 통해 입증된 뇌졸중 및 전신색전증 위험 감소 효과로 인해 순환기내과 전문의와 일차 진료 의사들 사이에서 지속적으로 채택이 확대되고 있습니다. 그러나 시장에는 눈에 띄는 제약도 존재합니다. 제네릭 항응고제에 비해 엘리퀴스의 높은 비용으로 인해 가격에 민감한 시장과 예산이 제한된 의료 시스템에서 접근성 문제가 발생하고 있습니다. 특허 만료에 대한 우려와 제네릭 의약품과의 경쟁 가능성은 시장 독점권에 대한 장기적인 위협이 될 수 있습니다. 또한 특정 환자군에서의 부작용 및 금기 사항으로 인해 보편적인 적용에는 한계가 있습니다. 이러한 어려움에도 불구하고 적응증 확대, 신흥 시장에서의 첨단 항응고요법에 대한 인식 증가, 개발도상국에서의 의료비 증가로 인해 큰 기회가 창출되고 있습니다. 정밀의료 접근법과 개인맞춤형 항응고제 도입 확대는 추가적인 성장의 길을 보여주고 있으며, 의료서비스가 부족한 지역에서의 전략적 제휴와 시장 확대 노력은 변화하는 항응고제 분야에서 이해관계자들에게 큰 매출 잠재력을 가져다 줄 수 있습니다.
이 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 글로벌 엘릭서 시장의 주요 기업 개요을 다양한 매개변수(회사 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등)에 따라 정리하여 수록하고 있습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- "세계의 엘리큐스 시장" 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 에리퀴스 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 엘리퀴스 시장 : 적응증별(2021-2033년)
제5장 세계의 엘리퀴스 시장 : 강도별(2021-2033년)
제6장 세계의 엘리퀴스 시장 : 연령층별(2021-2033년)
제7장 세계의 엘리퀴스 시장 : 제형별(2021-2033년)
제8장 세계의 엘리퀴스 시장 : 유통 채널별(2021-2033년)
제9장 세계의 엘리퀴스 시장 : 지역별(2021-2033년)
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고 문헌 및 분석 방법
KSA 26.06.10Eliquis Market is estimated to be valued at USD 8.33 Bn in 2026 and is expected to reach USD 12.03 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8.33 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.40% | 2033 Value Projection: | USD 12.03 Bn |
The global Eliquis market represents a critical segment within the pharmaceutical industry, focusing on one of the most widely prescribed anticoagulant medications worldwide. Eliquis (apixaban), developed by Bristol Myers Squibb and Pfizer, is a direct oral anticoagulant (DOAC) that belongs to the factor Xa inhibitor class of medications. This revolutionary drug has transformed the treatment landscape for various thromboembolic conditions, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The market encompasses the production, distribution, and commercialization of Eliquis across multiple therapeutic applications and geographical regions. As healthcare systems globally prioritize improved patient outcomes and seek alternatives to traditional anticoagulants like warfarin, Eliquis has emerged as a preferred choice due to its superior efficacy profile, reduced bleeding risks, and elimination of routine monitoring requirements. The market's evolution is characterized by increasing adoption rates among healthcare providers, expanding indications for use, and growing patient awareness about advanced anticoagulation therapies.
Market Dynamics
The global Eliquis market is primarily driven by several compelling factors that collectively fuel its expansion across international healthcare markets. The increasing prevalence of atrial fibrillation, venous thromboembolism, and other cardiovascular conditions worldwide serves as a fundamental growth driver, particularly amplified by aging demographics and lifestyle-related risk factors. Healthcare providers' growing preference for Eliquis over traditional anticoagulants like warfarin stems from its superior safety profile, predictable pharmacokinetics, and elimination of routine monitoring requirements, significantly improving patient compliance and quality of life. The drug's proven efficacy in reducing stroke risk and systemic embolism, supported by extensive clinical trial data, continues to drive adoption among cardiologists and primary care physicians. However, the market faces notable restraints including the high cost of Eliquis compared to generic anticoagulants, which creates accessibility challenges in price-sensitive markets and healthcare systems with budget constraints. Patent expiration concerns and potential generic competition pose long-term threats to market exclusivity, while adverse events and contraindications in certain patient populations limit universal applicability. Despite these challenges, significant opportunities emerge from expanding therapeutic indications, growing awareness about advanced anticoagulation therapies in emerging markets, and increasing healthcare expenditure in developing economies. The rising adoption of precision medicine approaches and personalized anticoagulation therapy presents additional growth avenues, while strategic partnerships and market expansion initiatives in underserved geographical regions offer substantial revenue potential for stakeholders in the evolving anticoagulant therapeutic landscape.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Eliquis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bristol Myers Squibb, Pfizer Inc., and other major pharmaceutical distributors and generic manufacturers
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Eliquis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Eliquis market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation
- Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
- Deep Vein Thrombosis
- Pulmonary Embolism
- Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism
- Venous Thromboembolism (VTE) and Reduction in the Risk of Recurrent VTE in Pediatric Patients
- Strength Insights (Revenue, USD Bn, 2021 - 2033)
- 5 mg
- 5 mg
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Dosage Form Insights (Revenue, USD Bn, 2021 - 2033)
- Oral Tablet
- Oral Suspension
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Bristol-Myers Squibb Company
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Eliquis Market, By Indication
- Global Eliquis Market, By Strength
- Global Eliquis Market, By Age Group
- Global Eliquis Market, By Dosage Form
- Global Eliquis Market, By Distribution Channel
- Global Eliquis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
- Epidemiology
- Adherence rate in U.S.
- Switch analysis in U.S.
- Patent Expiry Scenario
4. Global Eliquis Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Deep Vein Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pulmonary Embolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Venous Thromboembolism (VTE) and Reduction in the Risk of Recurrent VTE in Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Eliquis Market, By Strength, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- 5 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 5 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Eliquis Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Eliquis Market, By Dosage Form, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oral Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Eliquis Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Eliquis Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2022 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2022 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2022 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
